Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5551638 | 1.00 | MEN1 (0.40) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL6714850 | 0.91 | MEN1 (0.44) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL13455405 | 0.91 | MEN1 (0.44) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL319842 | 0.89 | MEN1 (0.43) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| Magnesium SCHEMBL30504225 | 0.87 | MEN1 (0.42) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL28428308 | 0.87 | MEN1 (0.42) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL6503220 | 0.85 | MEN1 (0.36) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL13455407 | 0.85 | MEN1 (0.39) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL23544814 | 0.82 | MEN1 (0.46) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL21169155 | 0.82 | MEN1 (0.43) | MEN1KMT2AKDM4CL3MBTL1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12398121-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NUVATION BIO INC. (US) | 2025-08-26 | — | — | US | disclosed |
| EP-3789472-B1 | POLYMERIZABLE LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION FOR OPTICAL ELEMENT, POLYMER, OPTICALLY ANISOTROPIC BODY, AND OPTICAL ELEMENT FOR DISPLAY DEVICE | LG CHEMICAL LTD (KR) | 2025-04-16 | — | — | EP | disclosed |
| US-20250034143-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, LLC (US) | 2025-01-30 | — | — | US | disclosed |
| US-11958854-B2 | Substituted xanthines and methods of use thereof | HYDRA BIOSCIENCES, LLC (US) | 2024-04-16 | — | — | US | disclosed |
| CN-111989384-B | Polymerizable liquid crystal compound, liquid crystal composition for optical element, polymer, optically anisotropic body, and optical element for display device | 株式会社LG化学 | 2023-09-08 | — | — | CN | disclosed |
| US-11674082-B2 | Polymerizable liquid crystal compound, liquid crystal composition for optical element, polymer, optically anisotropic body, and optical element for display device | LG CHEM, LTD. | 2023-06-13 | — | — | US | disclosed |
| US-20230122310-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2023-04-20 | — | — | US | disclosed |
| US-20230122310-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2023-04-20 | — | — | US | disclosed |
| US-20230040259-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, LLC (US) | 2023-02-09 | — | — | US | disclosed |
| US-20230040259-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, LLC (US) | 2023-02-09 | — | — | US | disclosed |
| EP-0585314-A1 | NOVEL HETEROCYCLIC CARBOXYLIC ACIDS. | NOVO NORDISK AS (DK) | 1994-03-09 | — | — | EP | disclosed |
| WO-1993013089-A1 | MACROCYCLIC POLYETHER CARBOXYLIC ACIDS | URBAN FRANK J (US) | 1993-07-08 | — | — | WO | disclosed |
| EP-0494925-A4 | POLYMERIZABLE (FUNCTIONALLY-SUBSTITUTED PHENYLENE) SEMI-RIGID CROWNS | — | 1993-01-20 | — | — | EP | disclosed |
| WO-1992020658-A1 | NOVEL HETEROCYCLIC CARBOXYLIC ACIDS | NOVO NORDISK A/S (DK) | 1992-11-26 | — | — | WO | disclosed |
| US-5142068-A | MONO- AND DI(FUNCTIONALLY-SUBSTITUTED PHENYLENE) SEMI-RIGID CROWNS AND PROCESSES FOR MAKING | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) | 1992-08-25 | — | — | US | disclosed |
| EP-0494925-A1 | POLYMERIZABLE (FUNCTIONALLY-SUBSTITUTED PHENYLENE) SEMI-RIGID CROWNS | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) | 1992-07-22 | — | — | EP | disclosed |
| WO-1991004971-A1 | POLYMERIZABLE (FUNCTIONALLY-SUBSTITUTED PHENYLENE) SEMI-RIGID CROWNS | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) | 1991-04-18 | — | — | WO | disclosed |
| US-4935442-A | Tetrahydrofuran-containing macrocyclic polyether carboxylic acids | PFIZER INC. (US) | 1990-06-19 | — | — | US | disclosed |
| US-4876367-A | ANIMAL GROWTH REGULATORS | PFIZER INC. (US) | 1989-10-24 | — | — | US | disclosed |
| US-4777270-A | INCREASE EFFICIENCY OF FEED UTILIZATION IN RUMINANTS | PFIZER INC. (US) | 1988-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12398121-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NCOA1, NCOR1, NCOA3 | MEN1 2250/4885KMT2A 2014/4885KDM4C 2613/4885 |
| US-11958854-B2 | Substituted xanthines and methods of use thereof | TRPC5, TRPC7, TRPC4 | MEN1 2331/4885KMT2A 4201/4885KDM4C 2391/4885 |
| US-20230040259-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | TRPC5, TRPC7, TRPC4 | MEN1 2331/4885KMT2A 4201/4885KDM4C 2391/4885 |
| US-20230122310-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NCOA1, NCOR1, NCOA3 | MEN1 2250/4885KMT2A 2014/4885KDM4C 2613/4885 |
| US-20250034143-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | TRPC5, TRPC7, TRPC4 | MEN1 2331/4885KMT2A 4201/4885KDM4C 2391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.